La Jolla Pharmaceutical Company

NasdaqCM:LJPC Stock Report

Market Cap: US$155.1m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

La Jolla Pharmaceutical Dividends and Buybacks

Dividend criteria checks 0/6

La Jolla Pharmaceutical does not have a record of paying a dividend.

Key information

n/a

Dividend yield

7.1%

Buyback Yield

Total Shareholder Yield7.1%
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

Innoviva to acquire La Jolla Pharma for $149M including debt

Jul 11

We Think La Jolla Pharmaceutical's (NASDAQ:LJPC) Robust Earnings Are Conservative

Nov 11
We Think La Jolla Pharmaceutical's (NASDAQ:LJPC) Robust Earnings Are Conservative

Our Take On La Jolla Pharmaceutical Company

Jul 02

La Jolla Pharmaceutical EPS misses by $0.14, beats on revenue

May 07

La Jolla Pharmaceutical's (NASDAQ:LJPC) Shareholders Are Down 82% On Their Shares

Mar 11
La Jolla Pharmaceutical's (NASDAQ:LJPC) Shareholders Are Down 82% On Their Shares

Market Sentiment Around Loss-Making La Jolla Pharmaceutical Company (NASDAQ:LJPC)

Feb 11
Market Sentiment Around Loss-Making La Jolla Pharmaceutical Company (NASDAQ:LJPC)

Industry Analysts Just Upgraded Their La Jolla Pharmaceutical Company (NASDAQ:LJPC) Revenue Forecasts By 18%

Jan 16
Industry Analysts Just Upgraded Their La Jolla Pharmaceutical Company (NASDAQ:LJPC) Revenue Forecasts By 18%

La Jolla Pharmaceutical rallies on exclusive licensing agreement with PAION

Jan 12

Should You Take Comfort From Insider Transactions At La Jolla Pharmaceutical Company (NASDAQ:LJPC)?

Jan 05
Should You Take Comfort From Insider Transactions At La Jolla Pharmaceutical Company (NASDAQ:LJPC)?

Could The La Jolla Pharmaceutical Company (NASDAQ:LJPC) Ownership Structure Tell Us Something Useful?

Dec 09
Could The La Jolla Pharmaceutical Company (NASDAQ:LJPC) Ownership Structure Tell Us Something Useful?

La Jolla Pharmaceutical EPS beats by $0.11, beats on revenue

Nov 09

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if LJPC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LJPC's dividend payments have been increasing.


Dividend Yield vs Market

La Jolla Pharmaceutical Dividend Yield vs Market
How does LJPC dividend yield compare to the market?
SegmentDividend Yield
Company (LJPC)n/a
Market Bottom 25% (US)1.4%
Market Top 25% (US)4.2%
Industry Average (Biotechs)2.3%
Analyst forecast (LJPC) (up to 3 years)n/a

Notable Dividend: Unable to evaluate LJPC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate LJPC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate LJPC's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as LJPC has not reported any payouts.


Discover strong dividend paying companies